Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

60 Degrees Pharmaceuticals (SXTPW) EBT Margin (2022 - 2025)

Historic EBT Margin for 60 Degrees Pharmaceuticals (SXTPW) over the last 4 years, with Q3 2025 value amounting to 529.43%.

  • 60 Degrees Pharmaceuticals' EBT Margin rose 10672900.0% to 529.43% in Q3 2025 from the same period last year, while for Sep 2025 it was 845.26%, marking a year-over-year increase of 7722800.0%. This contributed to the annual value of 1309.37% for FY2024, which is 1945500.0% up from last year.
  • As of Q3 2025, 60 Degrees Pharmaceuticals' EBT Margin stood at 529.43%, which was up 10672900.0% from 1717.42% recorded in Q2 2025.
  • 60 Degrees Pharmaceuticals' 5-year EBT Margin high stood at 8153.48% for Q3 2023, and its period low was 15126.2% during Q1 2023.
  • In the last 4 years, 60 Degrees Pharmaceuticals' EBT Margin had a median value of 1372.26% in 2024 and averaged 1722.9%.
  • Within the past 5 years, the most significant YoY rise in 60 Degrees Pharmaceuticals' EBT Margin was 155312600bps (2024), while the steepest drop was -97502000bps (2024).
  • Quarter analysis of 4 years shows 60 Degrees Pharmaceuticals' EBT Margin stood at 4492.13% in 2022, then tumbled by -136bps to 1628.06% in 2023, then soared by 48bps to 848.15% in 2024, then skyrocketed by 38bps to 529.43% in 2025.
  • Its EBT Margin was 529.43% in Q3 2025, compared to 1717.42% in Q2 2025 and 1147.79% in Q1 2025.